Age and fast initial response predict omalizumab retreatment in chronic urticaria
Michelle Meertens, Teddy Luijf, Esmee A.M. van Lindonk, Reineke Soegiharto, Salma Assil, Mehran Alizadeh Aghdam, Petra A. Kentie, André C. Knulst, Martijn B. A. van Doorn, Heike Röckmann
Abstract
We found that omalizumab can be discontinued to reveal disease remission and avoid drug exposure in patients with chronic urticaria.Higher age and fast initial response predict the need for retreatment and can be used to counsel patients in clinical practice.
Topics & Concepts
OmalizumabChronic urticariaMedicineDermatologyImmunologyImmunoglobulin EAntibodyUrticaria and Related ConditionsDermatology and Skin DiseasesCoagulation, Bradykinin, Polyphosphates, and Angioedema